Tagged with generics,

Malaysia Ch’ng Kien Peng, executive director of Xepa-Soul Pattinson, offers insights on the dynamic healthcare industry in Malaysia and the new government’s key role in supporting the local industry. He also details Xepa-Soul Pattinson’s strong footprint in the country as well as the company’s geographic expansion plans outside of Malaysia.  …

Malaysia Indranil Sen, managing director of Ranbaxy Malaysia, a Sun Pharma company, discusses the role of generics in the Malaysian pharmaceutical sector, and their strategy to lead the market, rather than becoming a “me too” generics company.   What have been your main goals that you have set out to achieve…

Europe European countries ranked by the levels of generics penetration within their domestic markets. Poland comes out on top by this measurement, with generic medicines making up a full 60.4% of market sales value, followed closely by Russia and Italy. At the other end of the scale, generics make up just…

Algeria Hepatitis C generics brought Beker to fame, but today its director general Rachid Kerrar discloses the new paths the company is exploring, such as new formulations and an increased focus on exports. He also praises the opportunities for business in pharmaceuticals in Algeria.   Rachid, Beker is most famous for…

Algeria Essam Farouk, President of MS Pharma provides insights on the success of its local manufacturing operations in Algeria, and the country’s potential to become an export hub. What recent changes have taken place within the MS Pharma group? We are planning expansions both inside and outside the Middle East and…

Algeria Sofiane Achi of El Kendi, one of Algeria’s leading pharma manufacturers, discusses the fresh ideas he has brought back to the company following a stint at Boehringer Ingelheim, manufacturing upgrades, and the country’s readiness for biosimilars. You decided to return to a company that you already know very well. How…

UK Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s strengths, the potential impact of Brexit on the pharmaceutical industry and the pricing structures in place in the UK.  …

UK Thembalath Ramachandran, chairman and managing director of one of the UK’s fastest growing generics manufacturers, Bristol Laboratories, describes why he chose to relocate from India to start his business, the company’s significant manufacturing footprint in the UK, and how the British government could be doing more to support homegrown manufacturers.…

Portugal Mario Madeira, general manager of Teva Portugal, highlights the milestones of the affiliate in Portugal, referencing the economic crisis and where Teva is now positioned in the country. In addition, he comments on Portugal’s great potential for digitalizing its healthcare sector. What are Teva Portugal’s priorities for 2018? “Teva is…

UK Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive double-digit market share in the UK, putting Accord firmly on track to attain their goal of becoming a top 5…

Portugal Experienced country manager, João Madeira, introduces Mylan’s new vision to be a global healthcare company serving patients across the world with their hybrid generic, OTC and innovative pharmaceutical business model which in the same breath sustains and innovates the healthcare system. Touching on themes of talent, biosimilars, and Portugal as…

Spain Joaquin Rodrigo, general director of Sandoz Spain and Portugal, introduces the company’s highly diversified generics and biosimilars portfolio in the region, gives his thoughts on Spain’s generics market, and outlines the rationale behind the creation of a national biosimilars association, BioSim.   Can you please start by introducing Sandoz and…